The Seventh Statin—Pitavastatin LIVALO® , Part 1: Clinical Studies

The Seventh Statin—Pitavastatin LIVALO® , Part 1: Clinical Studies

 

Pitavastatin is a synthetic HMG-CoA reductase inhibitor that significantly reduces the plasma levels of total cholesterol, LDL cholesterol, and triglycerides, while also causing modest elevation of the plasma HDL cholesterol level. Insights on pitavastatin from the clinical trials in the West and in Japan are discussed in this review.

n the Japanese dose-response trial, the LDL-C lowering effect of pitavastatin after 12 weeks was 34% (n=81) at a dose of 1 mg, 42% (n=75) at a dose of 2 mg, and 47% (n=76) at a dose of 4 mg.8 One report showed that 6 months administration of pitavastatin at 2 mg/d significantly reduced LDL-C, from 155 to 88 mg/dL, in 45 patients with diabetes.9